NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$217.8m

Last Updated

2021/05/05 23:25 UTC

Data Sources

Company Financials +

Executive Summary

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. More Details


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has EDAP TMS's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EDAP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: EDAP's weekly volatility (12%) has been stable over the past year.


Market Performance


7 Day Return

-9.8%

EDAP

-3.6%

US Medical Equipment

-1.6%

US Market


1 Year Return

209.5%

EDAP

34.9%

US Medical Equipment

52.8%

US Market

Return vs Industry: EDAP exceeded the US Medical Equipment industry which returned 34.9% over the past year.

Return vs Market: EDAP exceeded the US Market which returned 52.8% over the past year.


Shareholder returns

EDAPIndustryMarket
7 Day-9.8%-3.6%-1.6%
30 Day-28.9%4.1%1.3%
90 Day-19.9%3.3%3.5%
1 Year209.5%209.5%36.0%34.9%55.4%52.8%
3 Year177.9%177.9%74.7%70.5%63.5%53.2%
5 Year90.4%90.4%148.3%130.1%125.8%100.7%

Long-Term Price Volatility Vs. Market

How volatile is EDAP TMS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is EDAP TMS undervalued compared to its fair value and its price relative to the market?

6.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EDAP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EDAP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EDAP is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: EDAP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EDAP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EDAP is overvalued based on its PB Ratio (6x) compared to the US Medical Equipment industry average (4.9x).


Future Growth

How is EDAP TMS forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

44.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EDAP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: EDAP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EDAP's is expected to become profitable in the next 3 years.

Revenue vs Market: EDAP's revenue (19.1% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: EDAP's revenue (19.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EDAP's Return on Equity is forecast to be high in 3 years time


Past Performance

How has EDAP TMS performed over the past 5 years?

-38.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EDAP is currently unprofitable.

Growing Profit Margin: EDAP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EDAP is unprofitable, and losses have increased over the past 5 years at a rate of 38.7% per year.

Accelerating Growth: Unable to compare EDAP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EDAP is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.8%).


Return on Equity

High ROE: EDAP has a negative Return on Equity (-6.49%), as it is currently unprofitable.


Financial Health

How is EDAP TMS's financial position?


Financial Position Analysis

Short Term Liabilities: EDAP's short term assets (€45.4M) exceed its short term liabilities (€21.5M).

Long Term Liabilities: EDAP's short term assets (€45.4M) exceed its long term liabilities (€7.4M).


Debt to Equity History and Analysis

Debt Level: EDAP's debt to equity ratio (31.7%) is considered satisfactory.

Reducing Debt: EDAP's debt to equity ratio has increased from 25.1% to 31.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable EDAP has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: EDAP is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 7.8% per year.


Dividend

What is EDAP TMS current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EDAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EDAP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EDAP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EDAP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EDAP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Marc Oczachowski (50 yo)

14.17yrs

Tenure

Mr. Marc Oczachowski has been Chief Executive Officer of EDAP TMS SA since March 31, 2007 and its Executive Director since July 1, 2017. Mr. Oczachowski serves as Executive Chairman of the Board at EDAP TM...


Leadership Team

Experienced Management: EDAP's management team is seasoned and experienced (5.8 years average tenure).


Board Members

Experienced Board: EDAP's board of directors are seasoned and experienced ( 11.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.4%.


Top Shareholders

Company Information

EDAP TMS S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: EDAP TMS S.A.
  • Ticker: EDAP
  • Exchange: NasdaqGM
  • Founded: 1979
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$217.750m
  • Shares outstanding: 33.35m
  • Website: https://www.edap-tms.com

Number of Employees


Location

  • EDAP TMS S.A.
  • Parc d’Activites la Poudrette-Lamartine
  • 4/6, rue du Dauphiné
  • Lyon
  • Rhône-Alpes
  • 69120
  • France

Listings


Biography

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases in Asia, Fr...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/05 23:25
End of Day Share Price2021/05/05 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.